The biotech start-up adivo has set itself the goal of meeting the high demand for novel drugs for the treatment of cancer and chronic inflammatory diseases in dogs, with the potential to expand these activities to other animal species in the future. adivo GmbH is a spin-out of MorphoSys and was founded in March 2018 by Dr. Kathrin Ladetzki-Baehs and Dr. Markus Waldhuber. The headquarter of the company is now in the IZB.
“Today, therapeutic antibodies are one of the most successful classes of drugs in human medicine. The canine adivo antibody library represents a great and innovative approach that addresses the exciting field of veterinary medicine with products based on the MorphoSys human antibody generation concept,” commented Dr. Markus Enzelberger, Chief Scientific Officer of MorphoSys.
In August 2018, adivo announced that it had received seed financing from three investors. “We are very pleased to have gained three strong and reliable partners with the High-Tech Gründerfonds (HTGF), Occident Group AG and MorphoSys AG. They share our vision of driving innovation in veterinary medicine,” said Ladetzki-Baehs, CEO of adivo.